Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 12/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 12/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579626 | 0.79 | MEN1 (0.53) | MEN1KMT2ALPAR1LPAR5 | |
| SCHEMBL3577181 | 0.78 | MEN1 (0.55) | MEN1KMT2ATRPM8 | |
| SCHEMBL28152910 | 0.77 | HSD11B1 (0.53) | MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL3571440 | 0.76 | MLYCD (0.48) | MEN1KMT2ATRPM8 | |
| SCHEMBL3586090 | 0.76 | MLYCD (0.48) | MEN1KMT2ATRPM8 | |
| SCHEMBL29006698 | 0.72 | ACHE (0.61) | MEN1KMT2AALDH1A1TSHRLPAR1 | |
| SCHEMBL28730335 | 0.72 | MLYCD (0.39) | TRPM8ALDH1A1TSHRHSD17B10 | |
| SCHEMBL16923894 | 0.71 | TRPM8 (0.78) | MEN1KMT2ATRPM8EPHX1SERPINE1 | |
| SCHEMBL3575045 | 0.69 | SERPINE1 (0.47) | MEN1KMT2ATRPM8EPHX1SERPINE1 | |
| SCHEMBL850939 | 0.69 | ALDH1A1 (0.77) | KMT2AALDH1A1TSHRHSD17B10TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | MEN1 1293/4885KMT2A 341/4885TRPM8 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.